| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Musculoskeletal Disease Center, J. L. Pettis Memorial Veterans Affairs Medical Center, and Loma Linda University (D.B., S.M., C.S., D.J.B., X.Q.), Loma Linda, California 92357; and Department of Endocrinology, SoonChunHyang University Hospital (M.Y.), Seoul, 140-743 Korea
Address all correspondence and requests for reprints to: Dr. Xuezhong Qin, Musculoskeletal Disease Center, J. L. Pettis Veterans Affairs Medical Center (151), 11201 Benton Street, Loma Linda, California 92357. E-mail: xuezhong.qin{at}med.va.gov
Pregnancy-associated plasma protein-A (PAPP-A) has been identified as the insulin-like growth factor (IGF)-dependent IGF-binding protein-4 (IGFBP-4) protease produced by human fibroblasts. Recently, we found that serum proteases induced during human pregnancy cleaved IGFBP-4 in both an IGF-II-dependent and an IGF-II-independent fashion. This study sought to determine whether PAPP-A is the predominant IGFBP-4 protease in human pregnancy serum (PS) and to assess the in vitro role of serum PAPP-A. Immunoprecipitation with PAPP-A antibody effectively depleted PAPP-A from the PS and completely abolished both IGF-II-dependent and IGF-II-independent IGFBP-4 proteolytic activity in PS. Direct addition of PAPP-A antibody to PS completely blocked IGFBP-4 proteolysis and partially blocked IGFBP-5 proteolysis, but had no effect on IGFBP-3 proteolysis. To evaluate the role of serum PAPP-A, we tested whether PAPP-A in PS modulated the inhibitory activity of IGFBP-4 on IGF-II-induced cell proliferation in human osteosarcoma MG63 cells. The wild-type IGFBP-4 (WTBP-4; 200 ng/mL) failed to inhibit proliferation of the cells treated with PS (0.1% or 0.3%) alone or in combination with IGF-II (40 ng/mL), whereas the inhibitory effect of WTBP-4 was observed in the cells treated with nonpregnancy serum alone or in combination with IGF-II (P < 0.05). In contrast to WTBP-4, a protease-resistant IGFBP-4 was able to inhibit proliferation of the cells treated with PS alone or in combination with IGF-II (P < 0.05). In the presence of PAPP-A neutralizing antibody, the inhibitory effect of WTBP-4 on proliferation of the cells treated with IGF-II and PS was restored. In summary, these data demonstrate 1) that PAPP-A represents the predominant IGFBP-4 protease in PS; 2) that PAPP-A may in part contribute to IGFBP-5, but not IGFBP-3, proteolytic activity in PS; and 3) that PAPP-A enhances the bioactivity of IGFs in vitro by degrading IGFBP-4.
This article has been cited by other articles:
![]() |
C. Ganeff, G. Chatel, C. Munaut, F. Frankenne, J.-M. Foidart, and R. Winkler The IGF system in in-vitro human decidualization Mol. Hum. Reprod., January 1, 2009; 15(1): 27 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ning, A. G. P. Schuller, C. A. Conover, and J. E. Pintar Insulin-Like Growth Factor (IGF) Binding Protein-4 Is Both a Positive and Negative Regulator of IGF Activity in Vivo Mol. Endocrinol., May 1, 2008; 22(5): 1213 - 1225. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Conover Insulin-like growth factor-binding proteins and bone metabolism Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E10 - E14. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rehage, S. Mohan, J. E. Wergedal, B. Bonafede, K. Tran, D. Hou, D. Phang, A. Kumar, and X. Qin Transgenic Overexpression of Pregnancy-Associated Plasma Protein-A Increases the Somatic Growth and Skeletal Muscle Mass in Mice Endocrinology, December 1, 2007; 148(12): 6176 - 6185. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Harrington, R. D. Simari, and C. A. Conover Genetic Deletion of Pregnancy-Associated Plasma Protein-A Is Associated With Resistance to Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice Challenged With a High-Fat Diet Circ. Res., June 22, 2007; 100(12): 1696 - 1702. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S Miller, J. T Bronk, T. Nishiyama, H. Yamagiwa, A. Srivastava, M. E Bolander, and C. A Conover Pregnancy associated plasma protein-A is necessary for expeditious fracture healing in mice J. Endocrinol., March 1, 2007; 192(3): 505 - 513. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Qin, J. E. Wergedal, M. Rehage, K. Tran, J. Newton, P. Lam, D. J. Baylink, and S. Mohan Pregnancy-Associated Plasma Protein-A Increases Osteoblast Proliferation in Vitro and Bone Formation in Vivo Endocrinology, December 1, 2006; 147(12): 5653 - 5661. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. T. Resch, R. D. Simari, and C. A. Conover Targeted Disruption of the Pregnancy-Associated Plasma Protein-A Gene Is Associated with Diminished Smooth Muscle Cell Response to Insulin-like Growth Factor-I and Resistance to Neointimal Hyperplasia after Vascular Injury Endocrinology, December 1, 2006; 147(12): 5634 - 5640. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Prefumo, S. Canini, A. Crovo, D. Pastorino, P. L. Venturini, and P. De Biasio Correlation between first trimester fetal bone length and maternal serum pregnancy-associated plasma protein-A (PAPP-A) Hum. Reprod., November 1, 2006; 21(11): 3019 - 3021. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. T. Resch, C. Oxvig, L. K. Bale, and C. A. Conover Stress-Activated Signaling Pathways Mediate the Stimulation of Pregnancy-Associated Plasma Protein-A Expression in Cultured Human Fibroblasts Endocrinology, February 1, 2006; 147(2): 885 - 890. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Conover, L. K. Bale, S. C. Harrington, Z. T. Resch, M. T. Overgaard, and C. Oxvig Cytokine stimulation of pregnancy-associated plasma protein A expression in human coronary artery smooth muscle cells: inhibition by resveratrol Am J Physiol Cell Physiol, January 1, 2006; 290(1): C183 - C188. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kumar, S. Mohan, J. Newton, M. Rehage, K. Tran, D. J. Baylink, and X. Qin Pregnancy-associated Plasma Protein-A Regulates Myoblast Proliferation and Differentiation through an Insulin-like Growth Factor-dependent Mechanism J. Biol. Chem., November 11, 2005; 280(45): 37782 - 37789. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K Bale and C. A Conover Disruption of insulin-like growth factor-II imprinting during embryonic development rescues the dwarf phenotype of mice null for pregnancy-associated plasma protein-A J. Endocrinol., August 1, 2005; 186(2): 325 - 331. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Oesterreicher, W. F. Blum, B. Schmidt, T. Braulke, and B. Kubler Interaction of Insulin-like Growth Factor II (IGF-II) with Multiple Plasma Proteins: HIGH AFFINITY BINDING OF PLASMINOGEN TO IGF-II AND IGF-BINDING PROTEIN-3 J. Biol. Chem., March 18, 2005; 280(11): 9994 - 10000. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Matsui, B. Sonntag, S. S. Hwang, T. Byerly, A. Hourvitz, E. Y. Adashi, S. Shimasaki, and G. F. Erickson Pregnancy-Associated Plasma Protein-A Production in Rat Granulosa Cells: Stimulation by Follicle-Stimulating Hormone and Inhibition by the Oocyte-Derived Bone Morphogenetic Protein-15 Endocrinology, August 1, 2004; 145(8): 3686 - 3695. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Conover, L. K. Bale, M. T. Overgaard, E. W. Johnstone, U. H. Laursen, E.-M. Fuchtbauer, C. Oxvig, and J. van Deursen Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development Development, March 1, 2004; 131(5): 1187 - 1194. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. T. Resch, B.-K. Chen, L. K. Bale, C. Oxvig, M. T. Overgaard, and C. A. Conover Pregnancy-Associated Plasma Protein A Gene Expression as a Target of Inflammatory Cytokines Endocrinology, March 1, 2004; 145(3): 1124 - 1129. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Rivera and J. E. Fortune Selection of the Dominant Follicle and Insulin-Like Growth Factor (IGF)-Binding Proteins: Evidence that Pregnancy-Associated Plasma Protein A Contributes to Proteolysis of IGF-Binding Protein 5 in Bovine Follicular Fluid Endocrinology, February 1, 2003; 144(2): 437 - 446. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Y. C. Sun, M. T. Overgaard, C. Oxvig, and L. C. Giudice Pregnancy-Associated Plasma Protein A Proteolytic Activity Is Associated with the Human Placental Trophoblast Cell Membrane J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5235 - 5240. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zhang, E. P. Smith, H. Kuroda, W. Banach, S. D. Chernausek, and J. A. Fagin Targeted Expression of a Protease-resistant IGFBP-4 Mutant in Smooth Muscle of Transgenic Mice Results in IGFBP-4 Stabilization and Smooth Muscle Hypotrophy J. Biol. Chem., June 7, 2002; 277(24): 21285 - 21290. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Giudice, C. A. Conover, L. Bale, G. H. Faessen, K. Ilg, I. Sun, B. Imani, L.-F. Suen, J. C. Irwin, M. Christiansen, et al. Identification and Regulation of the IGFBP-4 Protease and Its Physiological Inhibitor in Human Trophoblasts and Endometrial Stroma: Evidence for Paracrine Regulation of IGF-II Bioavailability in the Placental Bed during Human Implantation J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2359 - 2366. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Miyakoshi, X. Qin, Y. Kasukawa, C. Richman, A. K. Srivastava, D. J. Baylink, and S. Mohan Systemic Administration of Insulin-Like Growth Factor (IGF)-Binding Protein-4 (IGFBP-4) Increases Bone Formation Parameters in Mice by Increasing IGF Bioavailability via an IGFBP-4 Protease-Dependent Mechanism Endocrinology, June 1, 2001; 142(6): 2641 - 2648. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |